Recently, another measurement method of the systemic inflammatory response, the lymphocyte to C-reactive protein (CRP) ratio (LCR) has been proposed for patients with rectal cancer, colorectal cancer, and gastric cancer [12–14]. The gene discussed is CRP; the disease is rectal cancer.